1
|
Bhatia J, Mazumdar M, Sutradhar B, Iyer L, Kumar V, Kothavade V. Impact of IGRT Frequency Upon Errors in Head and Neck Radiation: A Retrospective Analysis of Different Schedules. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
2
|
PATEL U, Patel H, Darji P, Patwari D, Shah P, Mazumdar M, Mandowara B, Shah R, Chotai N. SAT-422 SPECTRUM OF ACUTE KIDNEY INJURY IN DENGUE FEVER. Kidney Int Rep 2020. [DOI: 10.1016/j.ekir.2020.02.447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
3
|
Cozowicz C, Poeran J, Zubizarreta N, Liu J, Weinstein S, Pichler L, Mazumdar M, Memtsoudis S. Non-opioid analgesic modes of pain management are associated with reduced postoperative complications and resource utilisation: a retrospective study of obstructive sleep apnoea patients undergoing elective joint arthroplasty. Br J Anaesth 2019; 122:131-140. [DOI: 10.1016/j.bja.2018.08.027] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Revised: 08/02/2018] [Accepted: 08/21/2018] [Indexed: 10/28/2022] Open
|
4
|
Marqueen K, Ang C, Mazumdar M, Buckstein M, Ferket B. Cost-Effectiveness Analysis of Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres versus Sorafenib in Advanced Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
5
|
Chu BB, Mazumdar M. The Method of Correlated Temperatures for Determining the Hot Channel Factor in a Liquid Metal Fast Breeder Reactor. NUCL SCI ENG 2017. [DOI: 10.13182/nse73-a19485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- B. B. Chu
- Westinghouse Research Laboratories Pittsburgh, Pennsylvania 15235
| | - M. Mazumdar
- Westinghouse Research Laboratories Pittsburgh, Pennsylvania 15235
| |
Collapse
|
6
|
Poeran J, Varga AW, Zubizarreta N, Mazumdar M, Memtsoudis SG, Ayappa I, Rapoport DM, Burschtin OE. 0467 THE ROLE OF OBSTRUCTIVE SLEEP APNEA AND OBESITY IN POSTOPERATIVE OUTCOMES: A POPULATION-BASED STUDY IN PATIENTS UNDERGOING OPEN COLECTOMIES. Sleep 2017. [DOI: 10.1093/sleepj/zsx050.466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Mukherjee S, Manna A, Bhattacharjee P, Mazumdar M, Saha S, Chakraborty S, Guha D, Adhikary A, Jana D, Gorain M, Mukherjee SA, Kundu GC, Sarkar DK, Das T. Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4+ migrating cancer stem cells. Oncogene 2016; 35:4937-48. [DOI: 10.1038/onc.2016.26] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Revised: 11/02/2015] [Accepted: 11/27/2015] [Indexed: 12/18/2022]
|
8
|
|
9
|
Stundner O, Chiu YL, Sun X, Ramachandran SK, Gerner P, Vougioukas V, Mazumdar M, Memtsoudis SG. Sleep apnoea adversely affects the outcome in patients who undergo posterior lumbar fusion: a population-based study. Bone Joint J 2014; 96-B:242-8. [PMID: 24493191 DOI: 10.1302/0301-620x.96b2.31842] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Despite the increasing prevalence of sleep apnoea, little information is available regarding its impact on the peri-operative outcome of patients undergoing posterior lumbar fusion. Using a national database, patients who underwent lumbar fusion between 2006 and 2010 were identified, sub-grouped by diagnosis of sleep apnoea and compared. The impact of sleep apnoea on various outcome measures was assessed by regression analysis. The records of 84,655 patients undergoing posterior lumbar fusion were identified and 7.28% (n = 6163) also had a diagnostic code for sleep apnoea. Compared with patients without sleep apnoea, these patients were older, more frequently female, had a higher comorbidity burden and higher rates of peri-operative complications, post-operative mechanical ventilation, blood product transfusion and intensive care. Patients with sleep apnoea also had longer and more costly periods of hospitalisation. In the regression analysis, sleep apnoea emerged as an independent risk factor for the development of peri-operative complications (odds ratio (OR) 1.50, confidence interval (CI) 1.38;1.62), blood product transfusions (OR 1.12, CI 1.03;1.23), mechanical ventilation (OR 6.97, CI 5.90;8.23), critical care services (OR 1.86, CI 1.71;2.03), prolonged hospitalisation and increased cost (OR 1.28, CI 1.19;1.37; OR 1.10, CI 1.03;1.18). Patients with sleep apnoea who undergo posterior lumbar fusion pose significant challenges to clinicians.
Collapse
Affiliation(s)
- O Stundner
- Paracelsus Medical University, Department of Anaesthesiology, Perioperative Medicine and Intensive Care Medicine, Muellner Hauptstrasse 48, 5020 Salzburg, Austria
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Mohanty S, Saha S, Md S Hossain D, Adhikary A, Mukherjee S, Manna A, Chakraborty S, Mazumdar M, Ray P, Das K, Chakraborty J, Sa G, Das T. ROS-PIASγ cross talk channelizes ATM signaling from resistance to apoptosis during chemosensitization of resistant tumors. Cell Death Dis 2014; 5:e1021. [PMID: 24457965 PMCID: PMC4040699 DOI: 10.1038/cddis.2013.534] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2013] [Revised: 10/24/2013] [Accepted: 11/12/2013] [Indexed: 11/09/2022]
Abstract
With the existing knowledge of ATM's role in therapeutic resistance, the present study aimed at identifying the molecular mechanisms that influence ATM to oscillate between chemoresistance and chemosensitivity. We observed that the redox status of tumors functions as a major determinant of ATM-dependent ‘resistance-to-apoptosis' molecular switch. At a low reactive oxygen species (ROS) condition during genotoxic insult, the ATM/sumoylated-IKKγ interaction induced NFκB activation that resisted JNK-mediated apoptosis, whereas increasing cellular ROS restored ATM/JNK apoptotic signaling. A search for the upstream missing link revealed that high ROS induces oxidation and ubiquitin-mediated degradation of PIASγ, thereby disrupting PIASγ-IKKγ cross talk, a pre-requisite for IKKγ sumoylation and subsequent NFκB activation. Interruption in the PIASγ-mediated resistance pathway channels ATM signaling toward ATM/JNK pro-death circuitry. These in vitro results also translated to sensitive and resistant tumor allograft mouse models in which low ROS-induced resistance was over-ruled in PIASγ knockout tumors, while its overexpression inhibited high ROS-dependent apoptotic cues. Cumulatively, our findings identified an unappreciated yet critical combinatorial function of cellular ROS and PIASγ in regulating ATM-mediated chemosensitization of resistant tumors. Thus, therapeutic strategies employing ROS upregulation to inhibit PIASγ during genotoxic therapy may, in future, help to eliminate the problems of NFκB-mediated tumor drug resistance.
Collapse
Affiliation(s)
- S Mohanty
- Division of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata 700 054, India
| | - S Saha
- Division of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata 700 054, India
| | - D Md S Hossain
- Division of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata 700 054, India
| | - A Adhikary
- Division of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata 700 054, India
| | - S Mukherjee
- Division of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata 700 054, India
| | - A Manna
- Division of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata 700 054, India
| | - S Chakraborty
- Division of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata 700 054, India
| | - M Mazumdar
- Division of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata 700 054, India
| | - P Ray
- Division of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata 700 054, India
| | - K Das
- Division of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata 700 054, India
| | - J Chakraborty
- Division of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata 700 054, India
| | - G Sa
- Division of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata 700 054, India
| | - T Das
- Division of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata 700 054, India
| |
Collapse
|
11
|
Affiliation(s)
- P M Fleischut
- Department of Anesthesiology, New York-Presbyterian Hospital, Weill Medical College of Cornell University, 525 East 68th Street, M-308, New York, NY 10065, USA
| | | | | |
Collapse
|
12
|
Christos P, Mazumdar M, Mushlin A. The Influence of Surgical Subspecialty Training on In-Hospital Mortality for Cancer Procedures. Ann Epidemiol 2013. [DOI: 10.1016/j.annepidem.2013.06.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
13
|
Dy CJ, Franco N, Ma Y, Mazumdar M, McCarthy MM, Gonzalez Della Valle A. Complications after patello-femoral versus total knee replacement in the treatment of isolated patello-femoral osteoarthritis. A meta-analysis. Knee Surg Sports Traumatol Arthrosc 2012; 20:2174-90. [PMID: 21987361 DOI: 10.1007/s00167-011-1677-8] [Citation(s) in RCA: 91] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/09/2011] [Accepted: 09/12/2011] [Indexed: 12/18/2022]
Abstract
PURPOSE Both patellofemoral arthroplasty (PFA) and total knee arthroplasty (TKA) are successful in treating isolated patellofemoral osteoarthritis, but the complication rates after PFA are concerning. We performed a meta-analysis to compare the incidence of complications, re-operations, and revision following PFA and TKA for patellofemoral osteoarthritis. METHODS We systematically identified publications with patients who underwent PFA or TKA for patellofemoral osteoarthritis with minimum 1.5 year follow-up. Demographics, implant (TKA, first [1G] or second-generation [2G] PFA), complications, and cause of re-operations were extracted. Random-effects meta-analysis was used to pool incidence data, which was compared between groups using logistic regression to adjust for length of follow-up. RESULTS Twenty-eight observational studies and no randomized trials were included in this meta-analysis, which limits its generalizability. There was a higher likelihood of any re-operation (odds ratio 8.06) and revision (OR 8.11) in PFA compared to TKA. Re-operation (OR 4.33) and revision (OR 4.93) were more likely in 1G-PFA than 2G-PFA. When comparing 2G-PFA to TKA, there was no significant difference in re-operation, revision, pain, or mechanical complications. CONCLUSIONS Patients who undergo PFA rather than TKA are more likely to experience complications and require re-operation or revision, but subgroup analysis suggests a relation to implant design. There is no significant difference in re-operation, revision, pain, or mechanical complications between 2G-PFA and TKA. LEVEL OF EVIDENCE Systematic review of Level III therapeutic studies, Level III.
Collapse
Affiliation(s)
- C J Dy
- Department of Orthopaedic Surgery, Hospital for Special Surgery, 535 E 70th Street, New York, NY 10021, USA.
| | | | | | | | | | | |
Collapse
|
14
|
Blinder VS, Murphy MM, Vahdat LT, Gold HT, de Melo-Martin I, Hayes MK, Scheff RJ, Chuang E, Moore A, Mazumdar M. Employment after a breast cancer diagnosis: a qualitative study of ethnically diverse urban women. J Community Health 2012; 37:763-72. [PMID: 22109386 DOI: 10.1007/s10900-011-9509-9] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Abstract
Employment status is related to treatment recovery and quality of life in breast cancer survivors, yet little is known about return to work in immigrant and minority survivors. We conducted an exploratory qualitative study using ethnically cohesive focus groups of urban breast cancer survivors who were African-American, African-Caribbean, Chinese, Filipina, Latina, or non-Latina white. We audio- and video-recorded, transcribed, and thematically coded the focus group discussions and we analyzed the coded transcripts within and across ethnic groups. Seven major themes emerged related to the participants' work experiences after diagnosis: normalcy, acceptance, identity, appearance, privacy, lack of flexibility at work, and employer support. Maintaining a sense of normalcy was cited as a benefit of working by survivors in each group. Acceptance of the cancer diagnosis was most common in the Chinese group and in participants who had a family history of breast cancer; those who described this attitude were likely to continue working throughout the treatment period. Appearance was important among all but the Chinese group and was related to privacy, which many thought was necessary to derive the benefit of normalcy at work. Employer support included schedule flexibility, medical confidentiality, and help maintaining a normal work environment, which was particularly important to our study sample. Overall, we found few differences between the different ethnic groups in our study. These results have important implications for the provision of support services to and clinical management of employed women with breast cancer, as well as for further large-scale research in disparities and employment outcomes.
Collapse
Affiliation(s)
- V S Blinder
- Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Pumberger M, Chiu YL, Ma Y, Girardi FP, Mazumdar M, Memtsoudis SG. National in-hospital morbidity and mortality trends after lumbar fusion surgery between 1998 and 2008. ACTA ACUST UNITED AC 2012; 94:359-64. [PMID: 22371544 DOI: 10.1302/0301-620x.94b3.27825] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Increasing numbers of posterior lumbar fusions are being performed. The purpose of this study was to identify trends in demographics, mortality and major complications in patients undergoing primary posterior lumbar fusion. We accessed data collected for the Nationwide Inpatient Sample for each year between 1998 and 2008 and analysed trends in the number of lumbar fusions, mean patient age, comorbidity burden, length of hospital stay, discharge status, major peri-operative complications and mortality. An estimated 1 288 496 primary posterior lumbar fusion operations were performed between 1998 and 2008 in the United States. The total number of procedures, mean patient age and comorbidity burden increased over time. Hospital length of stay decreased, although the in-hospital mortality (adjusted and unadjusted for changes in length of hospital stay) remained stable. However, a significant increase was observed in peri-operative septic, pulmonary and cardiac complications. Although in-hospital mortality rates did not change over time in the setting of increases in mean patient age and comorbidity burden, some major peri-operative complications increased. These trends highlight the need for appropriate peri-operative services to optimise outcomes in an increasingly morbid and older population of patients undergoing lumbar fusion.
Collapse
Affiliation(s)
- M Pumberger
- Hospital for Special Surgery, 535 East 70th Street, New York, New York 10021, USA
| | | | | | | | | | | |
Collapse
|
16
|
Cha E, Barbieri C, Chromecki T, Dunning A, Lotan Y, Fajkovic H, Scherr D, Mazumdar M, Karakiewicz P, Shariat S. Clinical utility of NMP22 for the surveillance of patients with recurrent bladder cancer: a multi-center cross-sectional study. Journal of Men's Health 2011. [DOI: 10.1016/j.jomh.2011.08.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
17
|
Tagawa ST, Saran A, Akhtar NH, Goel S, Mileo G, Kung S, Beltran H, Milowsky MI, Mazumdar M, Wright JJ, Nanus DM. Final phase II results of NCI 6981: A phase I/II study of sorafenib (S) plus gemcitabine (GEM) and capecitabine (CAP) for advanced renal cell carcinoma (RCC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Nanus DM, Tagawa ST, Dutcher JP, Akhtar NH, Saran A, Mazumdar M, Milowsky MI, Gudas LJ. NCI 6896: A phase I trial of suberoylanilide hydroxamic acid (SAHA) and 13-cis retinoic acid in the treatment of patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.349] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
349 Background: Retinoid resistance in RCC inversely correlates with levels of intracellular retinol and retinyl esters suggesting that increasing intracellular levels of all-trans retinoic acid (RA) or enabling RA to become a more potent initiator of transcription will improve RA mediated anti-tumor effects. The combination of all-trans RA and a histone deacetylase (HDAC) inhibitor inhibited renal cancer cell proliferation and tumor growth in a xenograft model more than either drug alone. We performed a phase I clinical trial to evaluate the safety and preliminary efficacy of combining the oral HDAC inhibitor SAHA (vorinostat) plus oral 13-cis RA (isotretinoin) in patients with advanced RCC. Secondary endpoints include analysis of peripheral blood samples to study the effects on retinoid metabolites and retinoid related genes. Methods: Patients (pts) with metastatic RCC (any histology) who have failed at least two lines of prior therapy were eligible. Vorinostat (300 mg bid x 3 consecutive days per week + isotretinoin co-administered at 0.25 mg/kg, 0.375 mg/kg, or 0.5 mg/kg PO bid x 3 days per week in cohorts using standard 3+3 dose escalation. Dose limiting toxicity (DLT) was defined as any grade > 3 toxicity during the first cycle. Results: 14 pts have enrolled on the trial of which 12 are evaluable for toxicity (6 cohort 1; 3 cohort 2; 3 cohort 3) and 11 for tumor response. Common grade 1-2 toxicities included fatigue and GI effects (nausea, diarrhea, anorexia). One pt on dose-level 1 experienced a DLT (grade 3 depression). One patient experienced a partial response and 10 patients had stable disease lasting a median of 4 months (range 2–10 mos). Three patients progressed with brain metastases in the setting of stable systemic disease for at least 6 months. Pharmacokinetic and correlative studies examining expression of retinoid related genes are ongoing. Conclusions: The recommended phase II dose is vorinostat (300 mg bid) + isoretinoin (0.5 mg/kg PO bid) 3 days per week. The combination of vorinostat and isotretinoin was well tolerated, and there was evidence of antitumor activity in this heavily pretreated population of patients with refractory metastatic RCC. [Table: see text]
Collapse
Affiliation(s)
- D. M. Nanus
- Weill Cornell Medical College, New York, NY; Montefiore Medical Center North Division, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. T. Tagawa
- Weill Cornell Medical College, New York, NY; Montefiore Medical Center North Division, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J. P. Dutcher
- Weill Cornell Medical College, New York, NY; Montefiore Medical Center North Division, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - N. H. Akhtar
- Weill Cornell Medical College, New York, NY; Montefiore Medical Center North Division, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - A. Saran
- Weill Cornell Medical College, New York, NY; Montefiore Medical Center North Division, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - M. Mazumdar
- Weill Cornell Medical College, New York, NY; Montefiore Medical Center North Division, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - M. I. Milowsky
- Weill Cornell Medical College, New York, NY; Montefiore Medical Center North Division, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - L. J. Gudas
- Weill Cornell Medical College, New York, NY; Montefiore Medical Center North Division, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
19
|
Chromecki TF, Svatek RS, Holmäng S, Karakiewicz PI, Mazumdar M, Dunning A, Kamat AM, Tagawa ST, Scherr D, Shariat SF. Prognostic factors of cancer recurrence and progression in non-muscle-invasive urothelial carcinoma: A multicenter study of over 4,300 patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
249 Background: The outcomes of patients with non-muscle-invasive urothelial carcinoma of the bladder (NMIUCB) remain poorly understood. The aim of our study was to identify prognostic factors of cancer recurrence and progression in patients with primary UCB. Methods: We performed a combined analysis on individual data from 4,325 patients with primary NMIUCB. Results: Within a median follow-up of 64 months, 1,960 patients (45.4%) experienced disease recurrence, 498 (11.5%) experienced progression to muscle-invasive stage, 1,155 (26.7%) died of any cause, and 310 (7.2%) died of their cancer. In multivariable Cox regression analysis, advanced age, higher grade, larger tumor size, higher number of tumors, number of prior recurrences, and type of intravesical therapy were independent predictors of disease recurrence and progression. While treatment intravesical chemotherapy was only associated with decreased/delayed cancer recurrence, intravesical BCG therapy was associated with decreased/delayed cancer recurrence and progression. The predictive accuracies of the models for recurrence and progression were 63.5% and 71.3%, respectively. Conclusions: Even in a heterogenous patient population, BCG therapy appears to decrease frequency and delay time to cancer recurrence and progression in patients with NMIUCB. Predictive tools based on combination of multiple clinical variables which capture the biological and clinical potential of nonmuscle-invasive disease could help with patient counseling and individualized risk assessment for adjuvant intravesical therapy and clinical trial design. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. F. Chromecki
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - R. S. Svatek
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - S. Holmäng
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - P. I. Karakiewicz
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - M. Mazumdar
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - A. Dunning
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - A. M. Kamat
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - S. T. Tagawa
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - D. Scherr
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - S. F. Shariat
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| |
Collapse
|
20
|
Cha EK, Tirsar L, Shariat SF, Christos PJ, Mazumdar M, Hennenlotter J, Schwentner C, Mian C, Lodde M, Schmitz-Drager BJ. Use of immunocytology to predict bladder cancer presence in patients with asymptomatic hematuria. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
242 Background: The uCyt immunocytology assay detects cellular biomarkers for bladder cancer (BCa) in exfoliated urothelial cells. We assessed the performance of uCy for detecting BCa in patients undergoing initial evaluation for asymptomatic hematuria. Methods: Data from 1,182 subjects without a history of BCa undergoing evaluation for hematuria were collected at three centers: EuromedClinic/Urologie24, University of Tübingen, and Central Hospital of Bolzano. All subjects underwent standard workup (i.e., voided cytology, upper tract imaging, and cystoscopy) and immunocytology. Results: Overall, 245 subjects had BCa (20.7%). The sensitivity/specificity/negative predictive value for uCyt and cytology were 82.4%/86.6%/95.0% and 46.5%/94.9%/87.2%, respectively. uCyt (OR 18.3, p<0.001) and cytology (OR 2.9, p<0.001) were associated with BCa in a multivariable analysis. The base model (age, gender, smoking status, type of hematuria) predicted BCa with an accuracy of 74.1%. Addition of cytology to the base model improved predictive accuracy (PA) to 83.5% (p<0.001), while addition of uCyt to the base model improved PA to 90.1% (p<0.001). Addition of uCyt to Model 1 significantly improved PA (+7.6%, p<0.001), but addition of cytology to Model 2 did not (+1.0%, p=0.057). uCyt performed equally well in patients with microscopic and gross hematuria (OR 30 vs. 27), while cytology did not (OR 18 vs. 12). Conclusions: uCyt is a strong, independent predictor of BCa in patients with hematuria; it outperforms cytology. uCyt may help with patient counseling, quality of care optimization (referral prioritization), and possibly sparing unnecessary hematuria workup in patients at extremely low risk of BCa. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. K. Cha
- Weill Cornell Medical College, New York, NY; EuromedClinic, Furth, Germany; University of Tuebingen, Tuebingen, Germany; Central Hospital of Bolzano, Bolzano, Italy
| | - L. Tirsar
- Weill Cornell Medical College, New York, NY; EuromedClinic, Furth, Germany; University of Tuebingen, Tuebingen, Germany; Central Hospital of Bolzano, Bolzano, Italy
| | - S. F. Shariat
- Weill Cornell Medical College, New York, NY; EuromedClinic, Furth, Germany; University of Tuebingen, Tuebingen, Germany; Central Hospital of Bolzano, Bolzano, Italy
| | - P. J. Christos
- Weill Cornell Medical College, New York, NY; EuromedClinic, Furth, Germany; University of Tuebingen, Tuebingen, Germany; Central Hospital of Bolzano, Bolzano, Italy
| | - M. Mazumdar
- Weill Cornell Medical College, New York, NY; EuromedClinic, Furth, Germany; University of Tuebingen, Tuebingen, Germany; Central Hospital of Bolzano, Bolzano, Italy
| | - J. Hennenlotter
- Weill Cornell Medical College, New York, NY; EuromedClinic, Furth, Germany; University of Tuebingen, Tuebingen, Germany; Central Hospital of Bolzano, Bolzano, Italy
| | - C. Schwentner
- Weill Cornell Medical College, New York, NY; EuromedClinic, Furth, Germany; University of Tuebingen, Tuebingen, Germany; Central Hospital of Bolzano, Bolzano, Italy
| | - C. Mian
- Weill Cornell Medical College, New York, NY; EuromedClinic, Furth, Germany; University of Tuebingen, Tuebingen, Germany; Central Hospital of Bolzano, Bolzano, Italy
| | - M. Lodde
- Weill Cornell Medical College, New York, NY; EuromedClinic, Furth, Germany; University of Tuebingen, Tuebingen, Germany; Central Hospital of Bolzano, Bolzano, Italy
| | - B. J. Schmitz-Drager
- Weill Cornell Medical College, New York, NY; EuromedClinic, Furth, Germany; University of Tuebingen, Tuebingen, Germany; Central Hospital of Bolzano, Bolzano, Italy
| |
Collapse
|
21
|
Darvishian F, Rose AE, Christos PJ, Tu T, Shapiro RL, Berman RS, Pavlick AC, Kamino H, Mazumdar M, Osman I. Prognostic relevance of increased detection of lymphovascular invasion in primary melanoma using D2-40 and CD34 compared to routine histology. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Tu T, Ma MW, Monni S, Rose AE, Polsky D, Berman RS, Shapiro RL, Pavlick AC, Mazumdar M, Osman I. Prognostic factors for survival after first recurrence of melanoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
McCarville K, Flam A, Forst M, Swistel A, Osborne M, Moore A, Vahdat L, Klein P, Christos P, Mazumdar M, Chuang E. Differences in Breast Cancer Subtypes among Asian-American Women with Invasive Breast Cancer in New York City. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Specific breast cancer (BC) subtypes conferring distinct phenotypic and prognostic outcomes have been defined by molecular gene expression arrays. A recent study suggested that differences in BC subtypes exist among ethnic subgroups of Asian women in California. It has also been reported that there are differences in clinical outcomes among Asians with BC in the US, with Filipinos having a worse prognosis compared with other Asians. We sought to determine whether differences in BC subtypes exist among Asians in New York.Methods: Using outpatient registration records from Weill Cornell Breast Center and St. Vincent's Medical Center in New York City, we identified patients who were diagnosed with stage I, II, or III invasive BC between 1997 and 2007 who were of Chinese, Filipino, Japanese or Korean ethnicity. We reviewed pathology records according to an IRB approved protocol and recorded patient data for age, stage, grade, estrogen receptor (ER), progesterone receptor (PR) status, and HER-2/neu at diagnosis. Immunohistochemical surrogates for the four molecularly defined breast cancer subtypes were used according to accepted definitions (Luminal A: ER+Her2-; Luminal B: ER+ Her2+; Her2/neu: Her2+ ER-; Basal-like: ER-PR-, Her2-) Using chi-square analysis, we explored the relationship between ethnicity and BC subtypes.Results: 346 Asian women were identified with invasive breast cancer. Among the Chinese subgroup, 67% were of the Luminal A subtype, 15.3% were Luminal B, 10% were the Her2/neu subtype and 8.5% were Basal-like. Filipinos had a higher proportion of Luminal B cancers compared to the other ethnic groups. Filipinos and Koreans had a higher proportion of the Her2+/ER- subtype compared to Chinese and Japanese (P=0.004 by chi-square test). When considering all Her2/neu positive cancers, Filipinos had a significantly higher proportion of HER-2/neu positivity (46%) compared to Chinese (25%), Japanese (14%) and Korean (29%) groups (P=0.002). Filipinos and Koreans had a higher proportion of ER negative cancers and Grade III cancers compared to Chinese and Japanese (P=0.001 for ER status and P=0.01 for grade). In our series, Korean subjects were significantly younger than the other three ethnic groups (P<0.0001 by AVOVA test).Conclusions: Differences in BC subtypes exist among Asian women with invasive breast cancer in New York. Filipino women are significantly more likely to have HER-2/neu positive BC compared with Chinese, Japanese, and Korean women. Our results are supportive of results from a study in which differences in distribution of Her2/neu positive cancers among Asians in California were seen. Furthermore, these findings provide one explanation for the worse clinical outcome for Filipinos compared with other Asians that has been previously reported.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3067.
Collapse
Affiliation(s)
| | - A. Flam
- 2 Weill Cornell Medical College, NY,
| | - M. Forst
- 1 St. Vincent's Medical Center, NY,
| | | | | | - A. Moore
- 2 Weill Cornell Medical College, NY,
| | - L. Vahdat
- 2 Weill Cornell Medical College, NY,
| | - P. Klein
- 1 St. Vincent's Medical Center, NY,
| | | | | | - E. Chuang
- 2 Weill Cornell Medical College, NY,
| |
Collapse
|
24
|
Abstract
The relationship between pretreatment clinical features and survival was studied from patients treated on clinical trials for metastatic renal cell carcinoma (RCC) at the Memorial Sloan-Kettering Cancer Center. The primary analysis was performed on 670 patients treated with cytokines or chemotherapy, from which a multivariate model was derived to predict survival. Studies which followed addressed: (1) the survival of patients given interferon-alpha as first-line therapy; (2) a comparison of survival for patients treated with chemotherapy versus cytokine therapy; and (3) survival of patients with non-clear cell histology. Prospective identification of patients more likely to benefit from cytokine therapy is important as a stratification factor in phase III trials, and in risk-directed therapy.
Collapse
Affiliation(s)
- R J Motzer
- Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
| | | |
Collapse
|
25
|
Zakrzewski JA, Geraghty L, Hamilton H, Christos P, Krich D, Mazumdar M, Polsky D, Darvishian F, Pavlick A, Osman I. Prospective analysis of predictors of survival in melanoma patients with brain metastases. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9074 Background: Melanoma patients (pts) with brain metastases (BM) have limited survival, and BM remains an exclusion criterion in most clinical trials. A recent retrospective analysis at Memorial Sloan Kettering Cancer Center (MSKCC) identified 4 clinical variables that were associated with worse post BM survival (Raizer J et al, Neuro Oncol 2008). In this study, we investigated whether primary tumor features could improve the predictability of post BM survival and examined the reproducibility of the variables identified in MSKCC study. Methods: Melanoma pts with BM prospectively enrolled in an interdisciplinary database at NYU Medical Center from 2002 to 2008 were studied. Six primary tumor characteristics, 21 clinical variables, and treatments were examined. Univariate associations were analyzed using Kaplan Meier survival analysis and the independent effect of identified predictors was assessed by multivariate cox proportional hazards regression analysis. Results: Eighty-nine pts (36 F, 53 M, median age 57) were identified. Median post BM survival was 5.75 months. Median follow-up time based on survivors was 4.2 months. Ulceration and mitotic index ≥3/field were univariately associated with worse post BM survival (p=0.004, p=0.009 respectively). Age >65, ≥3 BM lesions, presence of neurological symptoms, and extracranial metastases were also univariately associated with worse post BM survival (the same 4 variables identified in MSKCC retrospective study). An additional 4 clinical parameters were significant by univariate analysis: frontal lobe location (p=0.01), bilateral lesions (p=0.01), ≥2 neurological symptoms (p=0.005), and weakness/fatigue (p<0.0001). After reproducing the significance of the 4 MSKCC variables in a multivariate model, ulceration of the primary tumor was also an independent predictor of post BM survival (hazard ratio [HR] = 2.75; 95% CI = 1.30, 5.83; p=0.008) whereas mitotic index ≥3/field was not (HR=1.24; 95% CI = 0.57, 2.71; p=0.59). Conclusions: Data suggest that ulceration of the primary melanoma might indicate an adverse biologic behavior that impacts post BM survival. Our data also lend independent support for the predictive model of post BM survival. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. A. Zakrzewski
- New York University School of Medicine, New York, NY; Weill Medical College of Cornell University, New York, NY
| | - L. Geraghty
- New York University School of Medicine, New York, NY; Weill Medical College of Cornell University, New York, NY
| | - H. Hamilton
- New York University School of Medicine, New York, NY; Weill Medical College of Cornell University, New York, NY
| | - P. Christos
- New York University School of Medicine, New York, NY; Weill Medical College of Cornell University, New York, NY
| | - D. Krich
- New York University School of Medicine, New York, NY; Weill Medical College of Cornell University, New York, NY
| | - M. Mazumdar
- New York University School of Medicine, New York, NY; Weill Medical College of Cornell University, New York, NY
| | - D. Polsky
- New York University School of Medicine, New York, NY; Weill Medical College of Cornell University, New York, NY
| | - F. Darvishian
- New York University School of Medicine, New York, NY; Weill Medical College of Cornell University, New York, NY
| | - A. Pavlick
- New York University School of Medicine, New York, NY; Weill Medical College of Cornell University, New York, NY
| | - I. Osman
- New York University School of Medicine, New York, NY; Weill Medical College of Cornell University, New York, NY
| |
Collapse
|
26
|
Hatcher D, Rose AE, Christos PJ, Mazumdar M, John M, Taneja SS, Lee P, Osman I. Impact of race on survival of prostate cancer patients treated with noncurative intent. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5069] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5069 Background: We previously reported that African American (AA) men have a higher recurrence rate than Caucasian (CA) men treated with radical prostatectomy at the New York Veteran Administration Medical Center (NY-VAMC), an equal access to care facility (J Urol. 2006). In the current study, we attempted to examine the differences in survival of AA and CA prostate cancer (PC) patients with clinically detected localized disease treated with non curative intent. We hypothesized that comparing patients whose PC was not altered by primary treatment might give a better idea about the difference, if any, of the natural history of PC in AA compared to CA patients. Methods: Men diagnosed with PC at NY-VAMC during 1990–2005 were identified. Inclusion criteria were: 1) biopsy confirmed PC; 2) no evidence of metastatic disease within 6 months after diagnosis; 3) no curative intent treatment. Results: The study included 530 men (288 AA and 242 CA) with median follow-up of 8.1 years (range: 0.6–17.6 years). AA men presented with significantly higher PSA compared to CA patients (median 18.5 versus 11.4 respectively, p = 0.004), however, there were no differences in age at presentation (median 73 versus 74, p = 0.98) or Gleason score (23% of AA and CA had Gleason >7, p = 0.92). Of the 530 patients, 198 (37%) are alive with disease, 67 (13%) died of prostate cancer, 206 (39%) died of other causes, and 59 (11%) died of unknown causes. AA patients had shorter median overall survival compared to CA patients (8 versus 9 years, respectively), however, the difference was not significant (p = 0.29). Factors most predictive of mortality by Cox regression multivariable analysis were PSA at diagnosis (p = 0.001), Gleason score (p = 0.04), and age of patient at diagnosis (p < 0.0001). Race was not an independent predictor of mortality in this model (p = 0.37). Competing risk analysis distinguishing the types of death is underway. Conclusions: The extended follow up available for our study cohort points to non PC related mortality as the major cause of death in patients treated with non-curative intent. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Hatcher
- New York University School of Medicine, New York, NY; Weill Cornell Medical College, New York, NY
| | - A. E. Rose
- New York University School of Medicine, New York, NY; Weill Cornell Medical College, New York, NY
| | - P. J. Christos
- New York University School of Medicine, New York, NY; Weill Cornell Medical College, New York, NY
| | - M. Mazumdar
- New York University School of Medicine, New York, NY; Weill Cornell Medical College, New York, NY
| | - M. John
- New York University School of Medicine, New York, NY; Weill Cornell Medical College, New York, NY
| | - S. S. Taneja
- New York University School of Medicine, New York, NY; Weill Cornell Medical College, New York, NY
| | - P. Lee
- New York University School of Medicine, New York, NY; Weill Cornell Medical College, New York, NY
| | - I. Osman
- New York University School of Medicine, New York, NY; Weill Cornell Medical College, New York, NY
| |
Collapse
|
27
|
Lavoie P, Rutledge J, Dawoud MA, Mazumdar M, Riina H, Gobin YP. Predictors and timing of hypotension and bradycardia after carotid artery stenting. AJNR Am J Neuroradiol 2008; 29:1942-7. [PMID: 18719034 DOI: 10.3174/ajnr.a1258] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Hypotension and bradycardia are common in carotid artery stenting (CAS) and are particularly worrisome in the high risk patient who is typically referred for CAS. The purpose of this work was to assess the incidence and predictors of hypotension and bradycardia and the risk of their delayed occurrence after CAS. MATERIALS AND METHODS A total of 53 men and 40 women (median age, 71 years) with symptomatic (57%) or asymptomatic (42%) carotid artery stenosis had CAS performed in our institution between December 2002 and January 2007. Patient vital sign records for the 12 hours post-CAS were analyzed. The relative decrease of blood pressure and pulse rate were used as primary end points, and the requirement of pressor or anticholinergic drugs was used as a surrogate end point. Significant predictors of hypotension and bradycardia were analyzed with a logistic regression model. Cumulative freedom from hypotension and bradycardia was calculated by using the Kaplan-Meier method. Negative predictive value (NPV) of screening for early hypotension and bradycardia was determined. RESULTS The incidence of hypotension, bradycardia, and both was 14%, 23%, and 15%, respectively. Drug intervention was required in 45 patients (48%). Asymptomatic stenosis was an independent predictor of hypotension and bradycardia. Stenosis proximity to the bifurcation and dilation percentage were independent predictors of the drug intervention requirement. Seven patients (8%) had new onset of hypotension or bradycardia later than 6 hours post-CAS. The NPV of early hypotension and bradycardia was 97% and 93%, respectively. CONCLUSION In this retrospective study, the risk of hypotension or bradycardia after CAS is significantly influenced by the degree of dilation performed, and the risk of their delayed occurrence may justify a minimum of 12 hours postprocedural vital sign monitoring.
Collapse
Affiliation(s)
- P Lavoie
- Division of Interventional Neuroradiology, Department of Public Health, Weill Medical College of Cornell University, New York, NY, USA
| | | | | | | | | | | |
Collapse
|
28
|
Blinder VS, Mahadeo M, Vahdat LT, Gold HT, De Melo-Martin I, Hayes MK, Scheff RJ, Moore A, Chuang E, Mazumdar M. Ethnicity and return to work in breast cancer survivors: An exploratory qualitative study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20532] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Wang G, Blochin E, Christos P, Pollens D, Yu JZ, Mazumdar M, Gerald W, Lee P, Oddoux C, Osman I. HDM2 overexpression and promoter polymorphism (SNP309) genotype: Comparison between African American (AA) and Caucasian American (CA) prostate cancer patients (pts). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Zakrzewski JA, Warycha MA, Ni Q, Shapiro RL, Berman RS, Pavlick AC, Polsky D, Mazumdar M, Osman I. Meta-analysis of sentinel lymph node positivity in thin melanoma (≤ 1mm). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Fournier D, Poirier D, Mazumdar M, Lin SX. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives. Eur J Med Chem 2008; 43:2298-306. [PMID: 18372081 DOI: 10.1016/j.ejmech.2008.01.044] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2007] [Revised: 01/22/2008] [Accepted: 01/24/2008] [Indexed: 10/22/2022]
Abstract
Type 1 17beta-hydroxysteroid dehydrogenase (17beta-HSD1) is a key steroidogenic enzyme that catalyses the reduction of steroid estrone into the most potent endogenous estrogen estradiol using the cofactor NAD(P)H. Bisubstrate inhibition is a good way to enhance the potency of inhibitors of cofactor-assisted enzymes. The design of a bisubstrate inhibitor of 17beta-HSD1, the estradiol/adenosine hybrid EM-1745, is reviewed and strategies for future designs of inhibitors are proposed.
Collapse
Affiliation(s)
- D Fournier
- Oncology and Molecular Endocrinology Research Center, CHUQ - Pavillon CHUL and Université Laval, 2705 Boulevard Laurier, Québec G1V 4G2, Canada
| | | | | | | |
Collapse
|
32
|
|
33
|
Royston P, Bacik J, Elson P, Manola JB, Mazumdar M. A consensus prognostic factor model for survival in patients with metastatic renal cell carcinoma: A Kidney Cancer Association’s International Kidney Cancer Working Group (IKCWG) study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5109] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5109 Background: Numerous well-designed retrospective studies of prognostic factors (pf) for survival (S) in metastatic renal cell carcinoma (mRCC) patients (pts) have been conducted since 1986. However, no single model for describing S in this population has been universally accepted. Methods: Authors of several existing prognostic indices, and others, formed the IKCWG to develop a single validated S model. The IKCWG has established a comprehensive database of previously reported clinical pf from 3748 previously untreated mRCC pts entered on institution review board approved clinical trials conducted by 11 centers in Europe and the United States from 1975–2002. Results: Median age at study entry was 58, 70% of pts were male, 89% had ECOG performance status (PS) 0 or 1; 75% had prior nephrectomy. 72%, 30%, and 19% of pts had lung, bone, and liver metastases (mets), respectively. 72% received interferon-a and/or interleukin-2 based treatments (tx); 25% were txd with chemotherapy/hormones only; 3% received other tx. 88% of pts have died; median S was 11.1 months (m). All examined factors except sex, age, and histology impacted S at p<.001 in univariable analysis. Multivariable analysis using a log-logistic model stratified by center and multivariable fractional polynomials was performed to identify independent predictors of S. Missing data were handled using multiple imputation methods. Using p=.0044 as the criterion for variable selection to avoid overly complex models, a model comprising tx, PS, number of met sites, interval from diagnosis to tx, and pre-tx hemoglobin, WBC, LDH, alkaline phosphatase and calcium was identified. The 25th and 75th percentiles of the prognostic index formed by multiplying each factor by its regression coefficient were used as cutpoints to form three risk (r) groups with median S times (SE) of: favorable r (n=937; 27.8 (0.4) m), intermediate r (n=1874; 11.4 (0.2) m), and poor r (n=937; 4.1 (0.1) m). Conclusions: 9 clinical factors can be used to model S in mRCC and form 3 distinct prognostic groups. Additional model building to determine if model complexity can be reduced further, validation in independent data and comparison to existing prognostic models are underway. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Royston
- MRC Clinical Trials Unit, London, United Kingdom; The EMMES Corporation, Rockville, MD; Cleveland Clinic, Cleveland, OH; Dana-Farber Cancer Institute, Boston, MA; Weill Medical College of Cornell, New York, NY
| | - J. Bacik
- MRC Clinical Trials Unit, London, United Kingdom; The EMMES Corporation, Rockville, MD; Cleveland Clinic, Cleveland, OH; Dana-Farber Cancer Institute, Boston, MA; Weill Medical College of Cornell, New York, NY
| | - P. Elson
- MRC Clinical Trials Unit, London, United Kingdom; The EMMES Corporation, Rockville, MD; Cleveland Clinic, Cleveland, OH; Dana-Farber Cancer Institute, Boston, MA; Weill Medical College of Cornell, New York, NY
| | - J. B. Manola
- MRC Clinical Trials Unit, London, United Kingdom; The EMMES Corporation, Rockville, MD; Cleveland Clinic, Cleveland, OH; Dana-Farber Cancer Institute, Boston, MA; Weill Medical College of Cornell, New York, NY
| | - M. Mazumdar
- MRC Clinical Trials Unit, London, United Kingdom; The EMMES Corporation, Rockville, MD; Cleveland Clinic, Cleveland, OH; Dana-Farber Cancer Institute, Boston, MA; Weill Medical College of Cornell, New York, NY
| |
Collapse
|
34
|
Schwartz L, Brody L, Brown K, Covey A, Tuorto S, Mazumdar M, Riedel E, Jarnagin W, Getrajdman G, Fong Y. Prospective, blinded comparison of helical CT and CT arterial portography in the assessment of hepatic metastasis from colorectal carcinoma. World J Surg 2006; 30:1892-9; discussion 1900-1. [PMID: 16855806 PMCID: PMC1578594 DOI: 10.1007/s00268-005-0483-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
OBJECTIVE This prospective blinded comparison of helical CT and helical CT arterial portography aimed to detect liver metastasis from colorectal carcinoma. METHODS AND MATERIALS 50 patients with colorectal carcinoma were evaluated comparing helical CT with helical CT arterial portography. Each imaging study was evaluated on a 5-point ROC scale by radiologists blinded to the other imaging findings, and the results were compared, with the surgical and pathologic findings as the gold standard. RESULTS Of the 127 lesions found at pathology identified as metastatic colorectal cancer, helical CT correctly identified 85 (69%) and CT portography 96 (76%). When subgroups with lesions <3 cm (48 patients) and patients with maximum tumor size <3 cm (18 patients) were considered, CT portography was always better than helical CT in terms of sensitivity, specificity, positive predictive value, and negative predictive value. ROC analysis adjusting for multiple lesions per patient revealed significantly greater area under the curve (AUC) for the subgroup of lesions <3 cm (CT-AUC of 77% and CT portography AUC of 81%; P = 0.002). CONCLUSIONS For identification of large metastases, helical CT and CT portography have similar yield. However, for detection of small liver metastases, CT portography remains superior for lesion detectability.
Collapse
Affiliation(s)
| | | | | | | | - S. Tuorto
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
| | - M. Mazumdar
- Department of Epidemiology and Biostatistics
| | - E. Riedel
- Department of Epidemiology and Biostatistics
| | - W. Jarnagin
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
| | | | - Y. Fong
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
- Correspondence and reprint requests should be addressed to: Yuman Fong, M.D., Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021 Phone: 1-212-639-2016 Fax: 1-646-422-2358
| |
Collapse
|
35
|
Bajorin DF, Nichols CR, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Einhorn L, Mazumdar M, Bosl GJ, Motzer RJ. Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4510] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4510 Background: First-line high-dose chemotherapy (HDCT) for poor-prognosis GCT PTS demonstrated improved relapse-free and overall survival compared to historical controls receiving conventional-dose regimens (JCO 1996;14:2546). Retrospective studies also showed correlations between long-term outcome and initial declines of alpha-fetoprotein (AFP) and/or human chorionic gonadotropin (HCG). This trial sought to determine: 1) if early intervention with HDCT resulted in an outcome superior to standard-dose chemotherapy and 2) whether AFP and HCG declines during cycles 1 & 2 correlated with long-term treatment outcome. Methods: PTS with untreated intermediate- or poor-risk GCT by International criteria (IGCCCG) were randomized to either 2 cycles of standard BEP (bleomycin, etoposide & cisplatin) followed by 2 cycles of HDCT (cyclophosphamide, etoposide, carboplatin) plus stem-cell rescue (BEP + HDCT) or to 4 cycles of BEP. The primary endpoint was the percent of PTS in complete response at 1 year (CR-1 yr). Based on an historical CR-1 yr of 45% for BEP, targeted accrual was 109 PTS/arm to detect a 20% improvement in PTS receiving BEP + HDCT with an alpha of 5% and 80% power. Randomization used random permuted blocks; strata were risk status (poor/intermediate) and treatment center. An independent DSMB performed one interim analysis of CR-1yr and survival in May 2000. Results: 219 PTS were randomized; 108 to BEP + HDCT and 111 to BEP alone. Final analysis demonstrated a CR-1yr of 52% for BEP + HDCT and 48% for BEP alone (P = .53 via actuarial methods). Slow marker decline PTS (AFP and/or HCG) during cycles 1 & 2 of BEP had a shorter progression-free and overall survival compared to satisfactory decline PTS (P ≤ .02) Among 70 PTS with unsatisfactory marker decline in cycles 1 & 2, the CR-1 yr was 61% for PTS receiving HDCT for cycles 3 & 4 versus 31% for those receiving 2 more cycles of BEP (P = .008). Conclusions: The routine inclusion of HDCT for intermediate- and poor-risk GCT does not improve treatment outcome. Serum marker decline during the first 2 cycles of BEP chemotherapy provides a clinically useful estimate of outcome. Research support provided by the NIH. [Table: see text]
Collapse
Affiliation(s)
- D. F. Bajorin
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health Science Center, Portland, OR; City of Hope National Medical Center, Duarte, CA; Dana-Farber Cancer Institute, Boston, MA; Nevada Cancer Institute, Las Vegas, NV; Indiana University, Indianapolis, IN; Weill Medical College of Cornell University, New York, NY
| | - C. R. Nichols
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health Science Center, Portland, OR; City of Hope National Medical Center, Duarte, CA; Dana-Farber Cancer Institute, Boston, MA; Nevada Cancer Institute, Las Vegas, NV; Indiana University, Indianapolis, IN; Weill Medical College of Cornell University, New York, NY
| | - K. A. Margolin
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health Science Center, Portland, OR; City of Hope National Medical Center, Duarte, CA; Dana-Farber Cancer Institute, Boston, MA; Nevada Cancer Institute, Las Vegas, NV; Indiana University, Indianapolis, IN; Weill Medical College of Cornell University, New York, NY
| | - J. Bacik
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health Science Center, Portland, OR; City of Hope National Medical Center, Duarte, CA; Dana-Farber Cancer Institute, Boston, MA; Nevada Cancer Institute, Las Vegas, NV; Indiana University, Indianapolis, IN; Weill Medical College of Cornell University, New York, NY
| | - P. G. Richardson
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health Science Center, Portland, OR; City of Hope National Medical Center, Duarte, CA; Dana-Farber Cancer Institute, Boston, MA; Nevada Cancer Institute, Las Vegas, NV; Indiana University, Indianapolis, IN; Weill Medical College of Cornell University, New York, NY
| | - N. J. Vogelzang
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health Science Center, Portland, OR; City of Hope National Medical Center, Duarte, CA; Dana-Farber Cancer Institute, Boston, MA; Nevada Cancer Institute, Las Vegas, NV; Indiana University, Indianapolis, IN; Weill Medical College of Cornell University, New York, NY
| | - L. Einhorn
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health Science Center, Portland, OR; City of Hope National Medical Center, Duarte, CA; Dana-Farber Cancer Institute, Boston, MA; Nevada Cancer Institute, Las Vegas, NV; Indiana University, Indianapolis, IN; Weill Medical College of Cornell University, New York, NY
| | - M. Mazumdar
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health Science Center, Portland, OR; City of Hope National Medical Center, Duarte, CA; Dana-Farber Cancer Institute, Boston, MA; Nevada Cancer Institute, Las Vegas, NV; Indiana University, Indianapolis, IN; Weill Medical College of Cornell University, New York, NY
| | - G. J. Bosl
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health Science Center, Portland, OR; City of Hope National Medical Center, Duarte, CA; Dana-Farber Cancer Institute, Boston, MA; Nevada Cancer Institute, Las Vegas, NV; Indiana University, Indianapolis, IN; Weill Medical College of Cornell University, New York, NY
| | - R. J. Motzer
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health Science Center, Portland, OR; City of Hope National Medical Center, Duarte, CA; Dana-Farber Cancer Institute, Boston, MA; Nevada Cancer Institute, Las Vegas, NV; Indiana University, Indianapolis, IN; Weill Medical College of Cornell University, New York, NY
| |
Collapse
|
36
|
Ocean AJ, Schnoll-Sussman F, Keresztes R, Chen X, Holloway S, Matthews N, Christos P, Mazumdar M, Wright J, Wadler S. Phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14040] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14040 Background: We are conducting a phase II trial of the proteasome inhibitor, PS-341, with or without irinotecan in pts with AGA. The combination of PS-341 and irinotecan has been studied in preclinical tumor models including a murine xenograft model of colon cancer, where the combination achieved significantly more tumor shrinkage than either agent alone. The primary objective of this study is to determine response rates, toxicities, progression-free survival, and overall survival in pts with AGA receiving PS-341 alone or in combination with irinotecan. Methods: All pts had gastric adenocarcinoma beyond the scope of surgical resection, measurable disease, and normal bone marrow, hepatic and renal function. All gave informed consent. In previously untreated patients, PS-341 was administered at 1.3 mg/m2 on days 1, 4, 8, and 11 as IV bolus every 21 days. Irinotecan was administered IV at 125 mg/m2 over 90 mins on days 1 and 8 every 21 days (Arm A). For previously treated patients, PS-341 was administered as a single agent at 1.3mg/m2 on days 1, 4, 8, 11 as an IV bolus every 21 days (Arm B). Radiologic evaluation and tumor measurements were performed every 8 weeks. Results: Thirty-seven pts have been enrolled; 29 are evaluable (4 never treated, 4 TETE). Twenty-two pts were treated in Arm A, and 11 in Arm B. All pts were eligible and the 29 treated pts were fully evaluable. Median age 58 (33–87); 26 males/7 females; median number of cycles received was 2.0. Most common toxicities: Grade 4 cardiac arrest (1), stomach perforation (1), leukopenia (2), diarrhea (1), edema (1); Grade 3 nausea (6), vomiting (7), diarrhea (4), febrile neutropenia (3), thrombocytopenia (6), anemia (6); Grade 5 death (3). Severe toxicities likely attributed to disease progression. Response rate was 33% for Arm A, 9% for Arm B. Progression-free survival was 1.8 mo. in Arm A, 1.4 mo. in Arm B. Median overall survival was 4.8 mo. in Arm A, 5.4 mo. in Arm B. Conclusions: The combination of PS-341 and irinotecan, a non-cisplatin containing therapy, is active in AGA and should be considered a key regimen. Monotherapy with PS-341 has a 9% response rate in this population of pre-treated patients with advanced disease. Accrual to this study is continuing. [Table: see text]
Collapse
Affiliation(s)
- A. J. Ocean
- Weill Medical College of Cornell University, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute, Bethesda, MD
| | - F. Schnoll-Sussman
- Weill Medical College of Cornell University, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute, Bethesda, MD
| | - R. Keresztes
- Weill Medical College of Cornell University, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute, Bethesda, MD
| | - X. Chen
- Weill Medical College of Cornell University, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute, Bethesda, MD
| | - S. Holloway
- Weill Medical College of Cornell University, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute, Bethesda, MD
| | - N. Matthews
- Weill Medical College of Cornell University, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute, Bethesda, MD
| | - P. Christos
- Weill Medical College of Cornell University, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute, Bethesda, MD
| | - M. Mazumdar
- Weill Medical College of Cornell University, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute, Bethesda, MD
| | - J. Wright
- Weill Medical College of Cornell University, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute, Bethesda, MD
| | - S. Wadler
- Weill Medical College of Cornell University, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute, Bethesda, MD
| |
Collapse
|
37
|
Sakharkar AJ, Singru PS, Mazumdar M, Subhedar N. Reproduction phase-related expression of beta-endorphin-like immunoreactivity in the nucleus lateralis tuberis of the female Indian major carp Cirrhinus mrigala: correlation with the luteinising hormone cells-ovary axis. J Neuroendocrinol 2006; 18:319-29. [PMID: 16629830 DOI: 10.1111/j.1365-2826.2006.01421.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The present study aimed to determine whether beta-endorphin immunoreactivity (bEP-ir) in the neurones of the nucleus lateralis tuberis (NLT) is linked to the seasonal cycle and shows correlation with the number of luteinising hormone (LH) cells in the pituitary gland and ovaries in the teleost, Cirrhinus mrigala. Although LH cells were moderately immunostained during the resting phase (December to January), the morphological profile suggested increased synthetic and secretory activity during the preparatory (February to April) and prespawning (May to June) phases. However, LH immunoreactivity was greatly reduced (P < 0.001) in the spawning (July to August) phase, suggesting massive discharge of the hormone; this pool was partly replenished in the postspawning (September to November) phase. The ovaries grew rapidly in the preparatory and prespawning phases; maximal size was attained during spawning, when ovulation occurred. Thereafter, the ovaries regressed. The NLT of C. mrigala is divisible into the pars lateralis (NLTl) and medialis (NLTm). During the postspawning and resting phases, bEP-ir was readily detectable in the NLTm as well as NLTl neurones. However, a steady reduction in the immunoreactivity was observed in the NLTm neurones during the preparatory through spawning phases (P < 0.001), suggesting a negative correlation with the LH cells-ovary axis. Thus, the inhibitory influence of beta-endorphin on the gonadotrophin-releasing hormone (GnRH)-LH axis appears to be attenuated during the preparatory through spawning phases. This may be necessary for the rapid stimulation of the axis culminating in spawning. Neurones of the NLTl also showed a gradual reduction in bEP-ir during the preparatory and prespawning phases (P < 0.01) and may therefore play a similar role. However, significant augmentation of the immunoreactivity was noticed in these neurones during the spawning phase (P < 0.001), the physiological significance of which is unknown. Although the present study demonstrated a temporal correlation between the beta-endorphin in the NLT, LH cells and the ovary, we suggest that the peptide in the NLTl and NLTm may show functional duality during the spawning phase.
Collapse
Affiliation(s)
- A J Sakharkar
- Department of Pharmaceutical Sciences, Nagpur University Campus, Nagpur, India
| | | | | | | |
Collapse
|
38
|
Schwartz LH, Colville JAC, Ginsberg MS, Wang L, Mazumdar M, Kalaigian J, Hricak H, Ilson D, Schwartz GK. Measuring tumor response and shape change on CT: esophageal cancer as a paradigm. Ann Oncol 2006; 17:1018-23. [PMID: 16641170 DOI: 10.1093/annonc/mdl058] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Accurate response assessment is essential for evaluating new cancer treatments. We evaluated the impact of Response Evaluation Criteria in Solid Tumors (RECIST), World Health Organization (WHO) criteria and tumor shape on response assessment in patients with metastatic esophageal cancer. PATIENTS AND METHODS In 19 patients with metastatic esophageal cancer in a phase II trial of bryostatin-1 and paclitaxel, response was retrospectively assessed for 89 lesions with RECIST and WHO criteria on baseline and serial follow-up CT scans. The eccentricity factor (EF) was introduced for measuring the degree to which tumor shape diverges from a perfect sphere [EF = radical1-(LPD/MD)(2), where LPD is the largest perpendicular diameter and MD is the maximal diameter]. RESULTS The disagreement rate in best overall response categorization between RECIST (unidimensional) and WHO (bidimensional) criteria was 26.3%. Change in eccentricity was significantly greater (P < 0.01) for patients with disagreement (mean 0.31, range 0-0.91). When the short axis was used for unidimensional lymph node measurement, disagreement between WHO and RECIST lessened. CONCLUSIONS Response assessment by WHO and RECIST differs substantially. Greater change in eccentricity is associated with greater discordance between WHO and RECIST. The discordance between WHO and RECIST may impact on how effective a therapy is judged to be.
Collapse
Affiliation(s)
- L H Schwartz
- Department of Radiology, Biostatistics and Epidemiology and Medicine, Memorial Sloan-Kettering Cancer Center, New York, 10021,USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Zhu DW, Garneau A, Mazumdar M, Zhou M, Xu GJ, Lin SX. Attempts to rationalize protein crystallization using relative crystallizability. J Struct Biol 2006; 154:297-302. [PMID: 16651006 DOI: 10.1016/j.jsb.2006.02.010] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2005] [Revised: 02/21/2006] [Accepted: 02/24/2006] [Indexed: 10/24/2022]
Abstract
Protein crystal growth (PCG) remains the bottleneck of crystallography despite many decades of study. The nucleation zone in the two-dimensional-phase diagram has been used to evaluate the relative crystallizability of proteins, which is expressed as a percentage over the phase area delineated by experimental protein and precipitating agent concentration ranges. For protein-salts which are subject to a direct temperature effect on solubility, as represented by Egg Lysozyme, a decrease in temperature augments the nucleation zone percentage whereas for those with retrograde solubility as a function of temperature, for example fructose-1,6-bisphosphatase in the presence and absence of AMP, an increase in temperature can significantly enhance the relative crystallizability. These results have been confirmed by the number of "hits" using PEGs as precipitating agents in Sparse Matrix Screen experiments for different proteins and are in excellent agreement with the relative crystallizability. The relationship between solubility dependence, relative crystallizability and crystallization success, has been evidenced. Such crystallizability can become a guide to identify efficient crystallization regions, providing a rational approach to PCG and structural biology.
Collapse
Affiliation(s)
- D-W Zhu
- Oncology and Molecular Endocrinology Research Center, CHUL and Laval University, Que., Canada G1V 4G2
| | | | | | | | | | | |
Collapse
|
40
|
Anselm IA, Anselm IM, Alkuraya FS, Salomons GS, Jakobs C, Fulton AB, Mazumdar M, Rivkin M, Frye R, Poussaint TY, Marsden D. X-linked creatine transporter defect: a report on two unrelated boys with a severe clinical phenotype. J Inherit Metab Dis 2006; 29:214-9. [PMID: 16601897 PMCID: PMC2393549 DOI: 10.1007/s10545-006-0123-4] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
We report two unrelated boys with the X-linked creatine transporter defect (CRTR) and clinical features more severe than those previously described with this disorder. These two boys presented at ages 12 and 30 months with severe mental retardation, absent speech development, hypotonia, myopathy and extra-pyramidal movement disorder. One boy has seizures and some dysmorphic features; he also has evidence of an oxidative phosphorylation defect. They both had classical absence of creatine peak on brain magnetic resonance spectroscopy (MRS). In one, however, this critical finding was overlooked in the initial interpretation and was discovered upon subsequent review of the MRS. Molecular studies showed large genomic deletions of a large part of the 3' end of the complete open reading frame of the SLC6A8 gene. This report emphasizes the importance of MRS in evaluating neurological symptoms, broadens the phenotypic spectrum of CRTR and adds knowledge about the pathogenesis of creatine depletion in the brain and retina.
Collapse
Affiliation(s)
- I A Anselm
- Department of Neurology, Children's Hospital Boston, Harvard Medical School, Massachusetts 02115, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Wang L, Schwartz LH, Mazumdar M, Smith A, Kemeny NE. Robustness of response: A new measure of response assessment: Its impact on metricies of response in colorectal cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Wang
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Sloan-Kettering Cancer Ctr, Cornell Univ, New York, NY; Weill Medcl Coll of Cornell Univ, New York, NY
| | - L. H. Schwartz
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Sloan-Kettering Cancer Ctr, Cornell Univ, New York, NY; Weill Medcl Coll of Cornell Univ, New York, NY
| | - M. Mazumdar
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Sloan-Kettering Cancer Ctr, Cornell Univ, New York, NY; Weill Medcl Coll of Cornell Univ, New York, NY
| | - A. Smith
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Sloan-Kettering Cancer Ctr, Cornell Univ, New York, NY; Weill Medcl Coll of Cornell Univ, New York, NY
| | - N. E. Kemeny
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Sloan-Kettering Cancer Ctr, Cornell Univ, New York, NY; Weill Medcl Coll of Cornell Univ, New York, NY
| |
Collapse
|
42
|
Elson PJ, Manola JB, Mazumdar M, Bacik JM, Supers SJ. Prognostic factors for survival in patients with metastatic renal cell carcinoma: a study from the Kidney Cancer Association’s International Kidney Cancer Working Group (IKCWG). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4533] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. J. Elson
- Cleveland Clinic Fdn, Cleveland, OH; Dana-Farber Cancer Inst, Boston, MA; Weill Medcl Coll of Cornell Univ, New York, NY; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - J. B. Manola
- Cleveland Clinic Fdn, Cleveland, OH; Dana-Farber Cancer Inst, Boston, MA; Weill Medcl Coll of Cornell Univ, New York, NY; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - M. Mazumdar
- Cleveland Clinic Fdn, Cleveland, OH; Dana-Farber Cancer Inst, Boston, MA; Weill Medcl Coll of Cornell Univ, New York, NY; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - J. M. Bacik
- Cleveland Clinic Fdn, Cleveland, OH; Dana-Farber Cancer Inst, Boston, MA; Weill Medcl Coll of Cornell Univ, New York, NY; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - S. J. Supers
- Cleveland Clinic Fdn, Cleveland, OH; Dana-Farber Cancer Inst, Boston, MA; Weill Medcl Coll of Cornell Univ, New York, NY; Memorial Sloan-Kettering Cancer Ctr, New York, NY
| |
Collapse
|
43
|
Grobmyer SR, Maki RG, Demetri GD, Mazumdar M, Riedel E, Brennan MF, Singer S. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol 2005; 15:1667-72. [PMID: 15520069 DOI: 10.1093/annonc/mdh431] [Citation(s) in RCA: 163] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND The purpose of this study was to retrospectively analyze the relationship between neo-adjuvant chemotherapy (NAC) and outcome in patients with high-grade extremity sarcomas. PATIENTS AND METHODS Inclusion criteria were high-grade, deep, >5 cm extremity soft tissue sarcomas. Patients diagnosed between 1990 and 2001 were treated with surgery only (n=282) or NAC containing doxorubicin/ifosfamide/mesna (AIM) (n=74). The stratified Cox proportional hazards model was used to test the effect of NAC on disease-specific survival and recurrence while adjusting for known prognostic factors. RESULTS NAC was associated with improved disease-specific survival for this cohort of patients (P=0.02). This overall improvement appears to be driven by the benefit of NAC on disease-specific survival for patient with tumors >10 cm. The 3-year disease-specific survival for tumors >10 cm was 0.62 (95% CI: 0.53-0.71) for patients not receiving NAC and 0.83 (95% CI: 0.72-0.95) for patients receiving NAC. CONCLUSION NAC with AIM was associated with a significant improvement in disease-specific survival in patients with high-grade extremity soft tissue sarcomas >10 cm. These data emphasize the need for further prospective clinical studies of neo-adjuvant or adjuvant chemotherapy for patients with large high-grade extremity sarcomas.
Collapse
Affiliation(s)
- S R Grobmyer
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | | | | | |
Collapse
|
44
|
Begum Z, Ghosh A, Sarkar S, Mukherjee J, Mazumdar M, Sarkar P, Chaudhuri S. Documentation of immune profile of microglia through cell surface marker study in glioma model primed by a novel cell surface glycopeptide T11TS/SLFA-3. Glycoconj J 2005; 20:515-23. [PMID: 15454689 DOI: 10.1023/b:glyc.0000043287.98081.15] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
STATEMENT OF THE PROBLEM The sheep erythrocyte membrane glycoprotein T11TS/SLFA-3 can form a ligand-receptor complex with CD2 present on immunocyte and exert stimuli for activation and proliferation. Regression of brain tumor with the application of T11TS indicates the probable role of microglia, the chief immunomodulatory cell within the brain compartment. In the present study microglial activation and immunophenotypic modulation were assessed in T11TS treated brain tumor-bearing animal models. Rat glioma models induced by chemical carcinogen ENU were treated with three consecutive doses of T11TS. Microglial cells from brain were isolated and assessed through E-rosette formation, SEM and FACS for CD2, MHC class II, CD25, and CD4. The preliminary indication of presence of CD2 on microglia through E-rosette formation was confirmed by SEM and FACS. MHC class II and CD2 single and double positive subpopulations exist, and their expression is also modulated in different doses of T11TS. A general trend of highest receptor saturation and microglial activation, measured through the activation marker CD25 and CD4 expression, was observed in 2nd dose of T11TS administration, which was then dampened via a complex immune feedback mechanism in the 3rd dose.
Collapse
Affiliation(s)
- Z Begum
- Cellular & Molecular Immunology Lab., Department of Physiology, Institute of Post Graduate Medical Education and Research (IPGME&R), 244B, A.J.C. Bose Road, Kolkata-700 020, India
| | | | | | | | | | | | | |
Collapse
|
45
|
Kondagunta GV, Bacik J, Bajorin D, Mazumdar M, Dobrzynski D, Sheinfeld J, Motzer RJ, Bosl GJ. Etoposide and cisplatin (EP) chemotherapy for good risk germ cell tumors (GCT): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - J. Bacik
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - D. Bajorin
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - M. Mazumdar
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - D. Dobrzynski
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - J. Sheinfeld
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - R. J. Motzer
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - G. J. Bosl
- Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
46
|
Chessin DB, Shia J, Mazumdar M, Moore HG, Paty P, Saltz L, Minsky B, Cohen AM, Wong WD, Guillem JG. Clinical assessment following preoperative combined modality therapy (CMT) for rectal carcinoma does not accurately predict pathologic response: A prospective analysis. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. B. Chessin
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J. Shia
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - M. Mazumdar
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - H. G. Moore
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - P. Paty
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - L. Saltz
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - B. Minsky
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - A. M. Cohen
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - W. D. Wong
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J. G. Guillem
- Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
47
|
Bacik J, Mazumdar M, Murphy BA, Fairclough DL, Eremenco S, Mariani T, Motzer RJ, Cella D. The functional assessment of cancer therapy–BRM (FACT–BRM): A new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res 2004; 13:137-54. [PMID: 15058795 DOI: 10.1023/b:qure.0000015297.91158.01] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
PURPOSE This paper reports on the development and validation of two biologic response modifier (BRM) subscales for use with the Functional Assessment of Cancer Therapy-General (FACT-G) quality of life (QOL) questionnaire. METHODS Using the FACT-G as a base, 17 additional questions related to symptoms common to interferon and retinoid therapy were developed. Data collected at baseline (n = 191) and week 2 (n = 168) in a randomized trial of interferon +/- 13-cis-retinoic acid in advanced renal cell carcinoma patients were used to validate this measure. RESULTS Using a combined empirical and conceptual approach, the 17 questions were reduced to 13 questions consisting of two subscales: 'BRM-physical' (7 items; baseline coefficient alpha(alpha) = 0.70; week-2 alpha = 0.75) and 'BRM-mental' (6 items; baseline alpha = 0.79; week-2 alpha = 0.78). Internal consistency of the trial outcome index (TOI) combining physical well-being, functional well-being and the BRM subscales, was 0.91 for baseline assessments and 0.92 for week 2. Discriminant validity was demonstrated for the TOI by its ability to differentiate among prognostic risk groups, and for the total FACT-G, TOI and total FACT-BRM scores by their ability to distinguish between groups differing in performance, response and toxicity status. CONCLUSIONS The 'BRM-physical' and 'BRM-mental' subscales can be combined with the FACT-G to form the 'FACT BRM' scale, useful for measuring QOL in cancer patients who are receiving treatment with biologic response modifiers.
Collapse
Affiliation(s)
- J Bacik
- Department of Epidemiology and Biostatistics a Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Chessin DB, Hartley J, Mazumdar M, Cordeiro P, Minsky B, Cohen A, Paty P, Weiser M, Wong D, Guillem JG. Rectus flap reconstruction decreases perineal wound complications following pelvic radiation and surgery: A cohort analysis. Ann Surg Oncol 2004. [DOI: 10.1007/bf02524170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
49
|
Berg WJ, Schwartz L, Yu R, Mazumdar M, Motzer RJ. Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. Invest New Drugs 2002; 19:317-20. [PMID: 11561691 DOI: 10.1023/a:1010609810517] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The aim of this study was to determine the antitumor activity of irofulven (6-hydroxymethylacylfulvene) in patients with advanced renal cell carcinoma (RCC). Eligible patients had advanced renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no prior treatment with chemotherapy, and no evidence of brain metastases. Irofulven was administered at a dose of 11 mg/m2 by 5-min intravenous infusion, on 5 consecutive days. Cycles were repeated every 28 days. Thirteen patients were enrolled in this study and 12 were evaluable for response. Of the twelve evaluable patients, no major responses were achieved. Eight patients had stable disease as best response. Toxicity included myelosuppression and gastrointestinal side effects. At the dose and schedule used in this trial, irofulven did not produce clinical response in RCC.
Collapse
Affiliation(s)
- W J Berg
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | |
Collapse
|
50
|
Korkaya H, Jameel S, Gupta D, Tyagi S, Kumar R, Zafrullah M, Mazumdar M, Lal SK, Xiaofang L, Sehgal D, Das SR, Sahal D. The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and activates MAPK. J Biol Chem 2001; 276:42389-400. [PMID: 11518702 DOI: 10.1074/jbc.m101546200] [Citation(s) in RCA: 121] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The hepatitis E virus (HEV) is the causative agent of hepatitis E, an acute form of viral hepatitis. The biology and pathogenesis of HEV remain poorly understood. We have used in vitro binding assays to show that the HEV ORF3 protein (pORF3) binds to a number of cellular signal transduction pathway proteins. This includes the protein tyrosine kinases Src, Hck, and Fyn, the p85alpha regulatory subunit of phosphatidylinositol 3-kinase, phospholipase Cgamma, and the adaptor protein Grb2. A yeast two-hybrid assay was used to further confirm the pORF3-Grb2 interaction. The binding involves a proline-rich region in pORF3 and the src homology 3 (SH3) domains in the cellular proteins. Competition assays and computer-assisted modeling was used to evaluate the binding surfaces and interaction energies of the pORF3.SH3 complex. In pORF3-expressing cells, pp60(src) was found to associate with an 80-kDa protein, but no activation of the Src kinase was observed in these cells. However, there was increased activity and nuclear localization of ERK in the pORF3-expressing cells. These studies suggest that pORF3 is a viral regulatory protein involved in the modulation of cell signaling. The ORF3 protein of HEV appears to be the first example of a SH3 domain-binding protein encoded by a virus that causes an acute and primarily self-limited infection.
Collapse
Affiliation(s)
- H Korkaya
- International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi 110067, India
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|